Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 2 ESSENCE study: One-year follow-up trial results. Significant reductions were found in the composite end point of cardiovascular death, myocardial infarction (MI), and recurrent angina with enoxaparin treatment compared to treatment with unfractionated heparin (UFH). The need for diagnostic catheterization and coronary revascularization was also significantly reduced with enoxaparin treatment. ESSENCE, Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-wave Coronary Events. Reprinted with permission from the American College of Cardiology Foundation, J Am Coll Cardiol 2000;36:693–8.
